Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Inclusion Criteria:

1. Participant must be at least 18 years of age inclusive, at the time of signing the informed consent.
2. DLBCL treated with CAR-T targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel)
3. PD/SD by PET-CT on the day of lymphodepletion
4. Capable of giving signed informed consent
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
6. No active CRS or ICANS at time of nivolumab administration

Exclusion Criteria:

1. Hypersensitivity to checkpoints inhibitors
2. CRS grade 3 and above or ICANS any grade on days 0-5 following CAR-T
3. AST (Aspartate transaminase) or ALT (Alanine transaminase) over 3 times the upper limit of normal (ULN) or total bilirubin over 3 times ULN
4. Serum creatinine over 1.5 times ULN or over 1.5 times baseline
5. History of or active autoimmune disease
6. Uncontrolled seizure activity and/or clinically evident progressive encephalopathy
7. Active diarrhea (more than 4 bowel movements per day)
8. Clinically significant uncontrolled illness
9. Active infection requiring antibiotics
10. Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection
11. Other active malignancy
12. Females only: Pregnant or breastfeeding